{"id":"khk4827","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"KHK4827 selectively inhibits Factor XIa, an enzyme involved in the contact phase of blood coagulation. By blocking Factor XIa, the drug reduces the amplification of thrombin generation while potentially preserving hemostasis through the extrinsic pathway, which may provide a favorable safety profile compared to conventional anticoagulants.","oneSentence":"KHK4827 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key enzyme in the intrinsic coagulation pathway.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:09.026Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboembolism prevention (in development)"}]},"trialDetails":[{"nctId":"NCT03957681","phase":"PHASE3","title":"A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2019-05-23","conditions":"Moderate to Severe Systemic Sclerosis","enrollment":100},{"nctId":"NCT04368403","phase":"PHASE1","title":"A Study of KHK4827 in Patients With Systemic Sclerosis","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2017-10-06","conditions":"Systemic Sclerosis","enrollment":8},{"nctId":"NCT02982005","phase":"PHASE3","title":"A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea","status":"COMPLETED","sponsor":"Kyowa Kirin Korea Co., Ltd.","startDate":"2017-01","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":62},{"nctId":"NCT02052609","phase":"PHASE3","title":"A Phase 3 Clinical Study of KHK 4827","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2014-02","conditions":"Psoriasis Vulgaris, Psoriatic Arthritis, Pustular; Psoriasis, Palmaris Et Plantaris","enrollment":155},{"nctId":"NCT04061252","phase":"PHASE3","title":"A Study of KHK4827 in Subjects With Palmoplantar Pustulosis","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2019-08-10","conditions":"Palmoplantar Pustulosis","enrollment":126},{"nctId":"NCT04614298","phase":"PHASE4","title":"A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis","status":"WITHDRAWN","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2021-01","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":""},{"nctId":"NCT01782937","phase":"PHASE3","title":"An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2013-02","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT01782924","phase":"PHASE3","title":"A Phase 3 Clinical Study of KHK4827","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2013-03","conditions":"Psoriasis","enrollment":145},{"nctId":"NCT01748539","phase":"PHASE2","title":"A Phase 2 Clinical Study of KHK4827","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2012-12","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":140},{"nctId":"NCT01488201","phase":"PHASE1","title":"A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2011-11","conditions":"Psoriasis","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Brodalumab"],"phase":"phase_3","status":"active","brandName":"KHK4827","genericName":"KHK4827","companyName":"Kyowa Kirin Co., Ltd.","companyId":"kyowa-kirin-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KHK4827 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key enzyme in the intrinsic coagulation pathway. Used for Thromboembolism prevention (in development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}